Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMRN NYSE:JNJ NASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRNBioMarin Pharmaceutical$59.20+0.1%$55.50$49.26▼$66.28$11.43B0.241.76 million shs1.59 million shsJNJJohnson & Johnson$257.82+0.3%$237.62$154.80▼$269.43$618.61B0.248.26 million shs5.24 million shsVRTXVertex Pharmaceuticals$480.25-1.1%$458.18$362.50▼$533.67$123.19B0.291.96 million shs1.15 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRNBioMarin Pharmaceutical+0.14%+0.70%+5.81%+6.72%+1.89%JNJJohnson & Johnson+0.25%-0.57%+7.17%+7.36%+64.35%VRTXVertex Pharmaceuticals-1.06%-9.32%+7.94%+8.10%+2.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRNBioMarin Pharmaceutical$59.20+0.1%$55.50$49.26▼$66.28$11.43B0.241.76 million shs1.59 million shsJNJJohnson & Johnson$257.82+0.3%$237.62$154.80▼$269.43$618.61B0.248.26 million shs5.24 million shsVRTXVertex Pharmaceuticals$480.25-1.1%$458.18$362.50▼$533.67$123.19B0.291.96 million shs1.15 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRNBioMarin Pharmaceutical+0.14%+0.70%+5.81%+6.72%+1.89%JNJJohnson & Johnson+0.25%-0.57%+7.17%+7.36%+64.35%VRTXVertex Pharmaceuticals-1.06%-9.32%+7.94%+8.10%+2.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMRNBioMarin Pharmaceutical 2.79Moderate Buy$88.5049.49% UpsideJNJJohnson & Johnson 2.74Moderate Buy$261.261.33% UpsideVRTXVertex Pharmaceuticals 2.84Moderate Buy$559.6116.52% UpsideCurrent Analyst Ratings BreakdownLatest BMRN, VRTX, and JNJ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/13/2026VRTXVertex Pharmaceuticals UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$545.00 ➝ $585.007/13/2026VRTXVertex Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$542.00 ➝ $560.007/13/2026JNJJohnson & Johnson TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$250.00 ➝ $300.007/13/2026JNJJohnson & Johnson Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$265.00 ➝ $287.007/10/2026JNJJohnson & Johnson Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$254.00 ➝ $263.007/8/2026JNJJohnson & Johnson Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$283.00 ➝ $284.007/8/2026JNJJohnson & Johnson CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$285.00 ➝ $298.007/7/2026VRTXVertex Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$543.00 ➝ $570.007/7/2026BMRNBioMarin Pharmaceutical Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$66.00 ➝ $62.007/6/2026JNJJohnson & Johnson HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$290.006/30/2026VRTXVertex Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMRNBioMarin Pharmaceutical$3.22B3.55$2.86 per share20.72$31.68 per share1.87JNJJohnson & Johnson$94.19B6.59$14.17 per share18.20$33.85 per share7.62VRTXVertex Pharmaceuticals$12.00B10.16$17.39 per share27.62$73.57 per share6.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMRNBioMarin Pharmaceutical$348.90M$1.3743.2110.590.458.29%6.50%5.07%8/3/2026 (Estimated)JNJJohnson & Johnson$26.80B$8.6529.8120.412.5121.83%32.60%13.29%7/15/2026 (Estimated)VRTXVertex Pharmaceuticals$3.95B$16.8628.4825.322.0735.51%23.86%17.13%8/3/2026 (Estimated)Latest BMRN, VRTX, and JNJ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/3/2026Q2 2026BMRNBioMarin Pharmaceutical$0.96N/AN/AN/A$939.23 millionN/A8/3/2026Q2 2026VRTXVertex Pharmaceuticals$4.72N/AN/AN/A$3.22 billionN/A7/15/2026Q2 2026JNJJohnson & Johnson$2.85N/AN/AN/A$25.02 billionN/A5/4/2026Q1 2026VRTXVertex Pharmaceuticals$4.24$4.47+$0.23$4.02$2.99 billion$2.99 billion4/14/2026Q1 2026JNJJohnson & Johnson$2.68$2.70+$0.02$2.14$23.60 billion$24.06 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBMRNBioMarin PharmaceuticalN/AN/AN/AN/AN/AJNJJohnson & Johnson$5.362.08%+5.25%61.97%64 YearsVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ALatest BMRN, VRTX, and JNJ DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/14/2026JNJJohnson & Johnsonquarterly$1.342.33%5/26/20265/26/20266/9/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMRNBioMarin Pharmaceutical0.235.814.20JNJJohnson & Johnson0.461.030.77VRTXVertex PharmaceuticalsN/A3.022.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMRNBioMarin Pharmaceutical98.71%JNJJohnson & Johnson69.55%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipBMRNBioMarin Pharmaceutical0.85%JNJJohnson & Johnson0.16%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMRNBioMarin Pharmaceutical3,221193.28 million191.64 millionOptionableJNJJohnson & Johnson138,2002.41 billion2.40 billionOptionableVRTXVertex Pharmaceuticals6,400253.80 million253.30 millionOptionableBMRN, VRTX, and JNJ HeadlinesRecent News About These CompaniesVertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Calamos Advisors LLC52 minutes ago | marketbeat.comVertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for InvestorsJuly 13 at 11:42 PM | finance.yahoo.comVertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for InvestorsJuly 13 at 7:01 PM | zacks.comDoes Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?July 13 at 6:41 PM | fool.comVortex Energy Corp. Announces Closing of LIFE OfferingJuly 13 at 6:41 PM | finance.yahoo.comDoes Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?July 13 at 2:50 PM | fool.comWhat to Expect From Vertex Pharmaceuticals' Next Quarterly Earnings ReportJuly 13 at 10:11 AM | barchart.comVertex Pharmaceuticals: Buy Rating Reaffirmed as Analyst Lifts Price Target from $598 to $600 on Robust CF Growth and Emerging Nephrology/Endocrinology UpsideJuly 13 at 6:11 AM | tipranks.comLGT Fund Management Co Ltd. Takes $2.26 Million Position in Vertex Pharmaceuticals Incorporated $VRTXJuly 13 at 5:36 AM | marketbeat.comFifth Third Bancorp Acquires 66,341 Shares of Vertex Pharmaceuticals Incorporated $VRTXJuly 13 at 3:43 AM | marketbeat.comAMF Tjanstepension AB Has $139.73 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTXJuly 13 at 3:12 AM | marketbeat.comCitizens Financial Group Inc. RI Purchases 6,421 Shares of Vertex Pharmaceuticals Incorporated $VRTXJuly 12 at 11:19 AM | marketbeat.comVertex (VRTX) Wins FDA Expansion For CASGEVY And Advances ALYFTREK In CanadaJuly 11 at 11:41 PM | finance.yahoo.comVertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology PowerhouseJuly 11 at 5:01 PM | marketbeat.comManning & Napier Advisors LLC Has $98.50 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTXJuly 11 at 10:39 AM | marketbeat.comCandriam S.C.A. Purchases 3,623 Shares of Vertex Pharmaceuticals Incorporated $VRTXJuly 11 at 9:19 AM | marketbeat.comWhy This Pharmaceutical Stock Jumped Close to 100% This WeekJuly 10, 2026 | fool.comIs This Biotech Stock a Buy Near Its 52-Week High?July 10, 2026 | fool.comIf You Invested $1000 in Vertex Pharmaceuticals a Decade Ago, This is How Much It'd Be Worth NowJuly 10, 2026 | finance.yahoo.comThe Long Climb Back For Ionis StockJuly 10, 2026 | trefis.comTBeyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act?July 10, 2026 | trefis.comTNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026Vertex’s Crinetics Deal Balances Growth with Integration RiskBy Chris Markoch | July 8, 2026The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.By Ryan Hasson | June 23, 2026BMRN, VRTX, and JNJ Company DescriptionsBioMarin Pharmaceutical NASDAQ:BMRN$59.20 +0.08 (+0.14%) Closing price 07/13/2026 04:00 PM EasternExtended Trading$60.02 +0.81 (+1.38%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.Johnson & Johnson NYSE:JNJ$257.82 +0.84 (+0.33%) Closing price 07/13/2026 03:59 PM EasternExtended Trading$258.11 +0.29 (+0.11%) As of 05:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Vertex Pharmaceuticals NASDAQ:VRTX$480.25 -5.14 (-1.06%) Closing price 07/13/2026 04:00 PM EasternExtended Trading$480.00 -0.25 (-0.05%) As of 04:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The SK Hynix IPO and 2027’s AI Memory Squeeze Why Welltower's Growth Story Might Outrun Its Rich Valuation Why Micron Is Doubling Down While the HBM Shortage Persists AMD's 5C Deal Positions It as a Direct NVIDIA Rival China's Helium Ban Could Reshape the AI Supply Chain The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions Analysts See Major Upside for These 5 Stocks One Short- and One Long-Term ETF for Quantum Computing Bulls Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
